Results 211 to 220 of about 275,402 (290)

Reduced-Dose Bendamustine as a First-Line Treatment of Follicular Lymphoma Is Associated With Poorer Prognosis. [PDF]

Cancer Med
Tanaka K, Takahata A, Noguchi Y, Okada K, Saito T, Mukae J, Osada Y, Suzuki K, Mizuchi D, Yamamoto K, Kumagai T, Oshikawa G, Mori T, Toyota S, Yamamoto M.   +14 more
europepmc   +1 more source

Diagnostic Yield of EBUS Mediastinal Cryobiopsy Versus TBNA in Suspected Lymphoproliferative Disorders: A Prospective Multicentre Study

Respirology, Volume 31, Issue 9, Page 903-911, September 2026.
We assessed the diagnostic yield of EBUS‐guided transbronchial mediastinal cryobiopsy (EBUS‐TBMC) compared with EBUS‐transbronchial needle aspiration (EBUS‐TBNA) in patients with suspected mediastinal lymphoproliferative disorders (LPDs). EBUS‐TBMC was superior to EBUS‐TBNA and achieved a high diagnostic yield in patients with suspected mediastinal ...
Yaniv Dotan, Ayal Romem, Elad Guber, Michael Kassirer, Daphne Felus, Nimrod Urtreger, Ophir Freund, Hanna A. Dawood, Boaz Tiran, Doron Cohn‐Schwartz, Sarah Borsekofsky, Amir Bar‐Shai, Evgeni Gershman   +12 more
wiley   +1 more source

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma. [PDF]

Hemasphere
Vitolo U, Falchi L, Andersson PO, Nijland M, Offner F, Snauwaert S, Christensen JH, Clausen MR, Fosså A, Prieto PG, Hawkes EA, Jørgensen JM, Karimi YH, Lewerin C, Vermaat JSP, Wahlin BE, Patah P, Morehouse C, Risum M, Li Z, Marek J, Brody JD.   +21 more
europepmc   +1 more source

Breaking Physiological Barriers in Women's Health: Mucoadhesive and Stimuli‐Responsive Nanomaterials

WIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 5, September/October 2026.
Drug delivery vehicles generated from biomaterials for women's health. In particular, the breast and the reproductive system, including the ovary, uterus, cervix, vagina, and the surrounding tissues, targeted drug delivery. BioRender. ABSTRACT Biomaterials are natural or synthetic molecules that exhibit biocompatibility, biodegradability, or ...
Maddox Parsons, Alivia R. Parker, Luke Schneider, Trisha Sullivan, Brittany E. Givens   +4 more
wiley   +1 more source

Rare Presentation of Sequential Mucosa-Associated Lymphoid Tissue Lymphoma, Follicular Lymphoma, and Chronic Lymphocytic Leukemia: A Case-Based Review. [PDF]

J Community Hosp Intern Med Perspect
Desai KJ, Patel AH, O'Dowd PT, Tworek JA, Misra PG, Ding L.   +5 more
europepmc   +1 more source

Risk Factors for Cutaneous Immune‐Related Adverse Events in the Japanese Population: A Retrospective Single‐Center Cohort Study

The Journal of Dermatology, Volume 53, Issue 9, Page 1245-1260, September 2026.
ABSTRACT Immune checkpoint inhibitor (ICI)‐driven alterations in the immune system can induce immune‐related adverse events (irAEs). Cutaneous irAEs are notable for being the most common and for their early onset; however, the risk factors underlying their development and severity remain unclear. In this study, we retrospectively analyzed 1224 Japanese
Tomoya Watanabe, Kohei Yamakawa, Miyu Kobayashi, Yusuke Saigusa, Yukie Yamaguchi   +4 more
wiley   +1 more source

Limited diagnostic utility of bone marrow sampling in PET-defined limited-stage follicular lymphoma. [PDF]

Br J Haematol
Solow M, Owen C, Stewart C, Cao JQ, Balogh A, Perry S, Shafey M, Street L, Puckrin R.   +8 more
europepmc   +1 more source

Demodex Infestation in Patients With Atopic Dermatitis Treated With Dupilumab: A Case–Control Study

The Journal of Dermatology, Volume 53, Issue 9, Page 1261-1266, September 2026.
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory skin disease in which dupilumab, an interleukin‐4 receptor alpha antagonist, has become a cornerstone therapy for moderate‐to‐severe disease. However, persistent facial and neck erythema and related symptoms have been increasingly reported during dupilumab treatment, and the underlying ...
Pinar Dursun, Ayse Nur Saribas Yildirim, Ayca Yazici   +2 more
wiley   +1 more source

Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial. [PDF]

Hemasphere
Maher N, Moia R, Almasri M, Cividini L, Genuardi E, Cosentino C, Soscia R, Assanto GM, Tavarozzi R, Vegliante MC, Lorenzi L, Andorno A, Arcaini L, Ragaini S, Puccini B, Patti C, Santoro A, Margiotta-Casaluci G, Zilioli VR, Zanni M, Ronconi S, Di Raimondo F, Arcari A, Califano C, Castellino C, Conconi A, Perrone T, Mannina D, Plenteda C, Alesiani F, Rossi FG, Carella AM, Marcheselli L, Galimberti S, Ciavarella S, Bomben R, Del Giudice I, Ladetto M, Gaidano G, Luminari S, Ferrero S.   +40 more
europepmc   +1 more source

Comparative effectiveness of chimeric antigen receptor (CAR) T‐cell therapy versus historical controls in patients with relapse/refractory aggressive B‐cell lymphoma: An indirect treatment comparison in the real‐world setting

British Journal of Haematology, Volume 209, Issue 3, Page 1230-1238, September 2026.
Summary Single‐arm studies demonstrate dramatic improvements in survival in patients with relapsed/refractory (R/R) aggressive B‐cell lymphomas but with significant toxicities and at exceptionally high costs. The objective of this study was to evaluate the real‐world health outcomes of aggressive B‐cell lymphoma patients treated with publicly funded ...
Pierre J. A. Villeneuve, Lee Mozessohn, Nibene H. Somé, Rebecca E. Mercer, Lisa Masucci, Tom Kouroukis, Chris Bredeson, Suriya Aktar, Qi Guan, Anca Prica, Christine I. Chen, Danielle Rodin, Matthew Cheung, Munaza Chaudhry, Scott Gavura, Cassandra McKay, William W. L. Wong, Kelvin K. W. Chan   +17 more
wiley   +1 more source